Home > Journals > Minerva Cardiology and Angiology > Past Issues > Articles online first > Minerva Cardiology and Angiology 2021 Oct 29

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as
Share

 

 

Minerva Cardiology and Angiology 2021 Oct 29

DOI: 10.23736/S2724-5683.21.05794-X

Copyright © 2021 EDIZIONI MINERVA MEDICA

language: English

Reverse remodelling in diabetic cardiomyopathy: the role of extracellular matrix

Ibrahim AYKAC, Bruno K. PODESSER, Attila KISS

Ludwig Boltzmann Institute for Cardiovascular Research at the Center for Biomedical Research, Medical University of Vienna, Vienna, Austria


PDF


Diabetic patients are prone to suffer from cardiovascular disease, specifically from ischemic heart disease and diabetic cardiomyopathy, which have a huge impact on morbidity and mortality worldwide. Cardiac fibrosis due to alteration of the extracellular matrix (ECM) remodelling is often observed in diabetes and myocardial fibrosis is an important part of cardiac remodeling that leads to heart failure and death. At single-cell level, the ECM govern, metabolism, motility, orientation and proliferation. However, in pathological condition such as diabetes, changes in ECM lead to fibrosis and subsequently cardiac stiffness and cardiomyocytes dysfunction. Anti-diabetic drugs, particularly sodium-glucose cotransporter-2 (SGLT2) inhibitors have anti-fibrotic effects, and may promote ECM reverse remodelling. In this mini-review, the mechanisms and the role of ECM remodelling and reverse remodelling as a potential therapeutic targets for diabetic cardiomyopathy are discussed.


KEY WORDS: Diabetes; Extracellular matrix; Reverse remodelling; Fibrosis

top of page